Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Optimizing Safety of Cilta-Cel in Relapsed MM: Modifiable Risk Factors for Delayed Neurotoxicity and NRM

Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Optimizing Safety of Cilta-Cel in Relapsed MM: Modifiable Risk Factors for Delayed Neurotoxicity and NRM

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

ID 1034 – Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Studies/trials discussed:

ID 1034 – Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
Tagged